✦ LIBER ✦

Delivered Dose: A Drug-centric Phenotype for Chemotherapy Dose Individualization

✍ Scribed by Y. Bruce Yu

Book ID: 106493794
Publisher: Springer US
Year: 2009
Tongue: English
Weight: 84 KB
Volume: 26
Category: Article
ISSN: 0724-8741
DOI: 10.1007/s11095-009-9913-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A trial of individual dose intensity and

A trial of individual dose intensity and relative performance factors in tegafur maintenance chemotherapy for head and neck cancer

✍ S. Sawaki; H. Watanabe; T. Shine; T. Kubota; S. Komiyama; T. Umezaki; I. Nahm 📂 Article 📅 1993 🏛 Springer-Verlag 🌐 English ⚖ 394 KB

2035 POSTER NEAT-A: Accelerated sequenti

2035 POSTER NEAT-A: Accelerated sequential epirubicin followed by higher dose 14 day CMF, using pegfilgrastim, is a feasible alternative for delivering dose dense E-CMF chemotherapy in early breast cancer

✍ S. Bowden; L. Gross; C.J. Poole; L. Hiller; R.K. Agrawal; K.F. McAdam; H.M. Earl 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 81 KB

The multifractionated, twice-weekly dose

The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen : A Phase I–II study of paclitaxel, cisplatin, and vinorelbine

✍ Jacob J. Lokich; Norwood Anderson; Murray Bern; Frank Coco; Edward Dow 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 2 views

## Background: Paclitaxel, cisplatin, and vinorelbine are three important antineoplastic drugs with different mechanisms of cell kill. a combination of these three drugs potentially could have additive therapeutic effects. methods. the three-drug combination (designated tpn) was administered on a t

91 Delivered dose intensity with an indu

91 Delivered dose intensity with an induction chemotherapy (CT) by ifosfamide, etoposide and anthracyclin for patients (PTS) with small cell lung cancer (SCLC): A report by the european lung cancer working party

✍ M. Paesmans; J.P. Sculier; G. Bureau; V. Giner; J. Thiriaux; P. Mommen; J. Klast 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 306 KB

A phase II trial of individualized respo

A phase II trial of individualized response-based induction chemotherapy (IC) of mitomycin-C, vindesine, cisplatin (MVP) followed by thoracic radiotherapy (TRT) with daily low-dose carboplatin (CBDCA) for the treatment of unresectable stage III non-small-cell lung cancer (NSCLC)

✍ Shinbo, T; Makino, M; Tsukada, H; Yokoyama, A; Saitou, M; Kurita, Y 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 230 KB